Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.

Abstract: A system for handling transactions in a communication network, wherein the transactions include at least one technology-dependent request for a given content made by a requester to at least one server. The system operates based on an access content list including permit/deny access clauses regulating access of the requesters to the contents by the server. A processing module, configured for detecting the technology-dependent request, and extracting therefrom information identifying the requester making the request and the content requested, is provided. A corresponding technology independent access content entry, adapted to be checked against the access content list to derive permit/deny information concerning the request detected, can thus be generated. The request is handled as a function of the permit/deny information derived and thus, e.g., forwarded toward the server or either dropped or forwarded to an alternative destination.

Abstract: A system for handling transactions in a communication network, wherein the transactions include at least one technology-dependent request for a given content made by a requester to at least one server. The system operates based on an access content list including permit/deny access clauses regulating access of the requesters to the contents by the server. A processing module, configured for detecting the technology-dependent request, and extracting therefrom information identifying the requester making the request and the content requested, is provided. A corresponding technology independent access content entry, adapted to be checked against the access content list to derive permit/deny information concerning the request detected, can thus be generated. The request is handled as a function of the permit/deny information derived and thus, e.g., forwarded toward the server or either dropped or forwarded to an alternative destination.

Abstract: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin. excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.

Abstract: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.

Abstract: The present invention is directed to use of an agent which is able to prevent pathological overexpression of TGF-&bgr; gene in vivo for the preparation of a medicament for the treatment of disorders connected with AP-1 mediated TGF-&bgr; gene expression, except use of sulodexide, low molecular weight heparin derivatives obtained by chemical or enzymatic depolymerization, chemically modified heparin derivatives and low molecular weight dermatan sulfates obtained by chemical or enzymatic depolymerization for the treatment of diabetic nephropathy. Further, the invention provides convenient, fast in vitro methods to assess the value of agents useful for the said disorders.

Abstract: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.

Abstract: The use of some glycosaminoglycans like sulodexide, low molecular weight heparin and low molecular weight dermatan sulfate and of the medicines by parenteral use that contain them in the treatment of patients suffering from chronic renal insufficiency subjected to peritoneal dialysis is described. The effectiveness of this use has been shown both by pharmacological studies carried out in nephrectomized rats to whom a peritoneal damage has been caused and by clinical studies carried out in patients suffering from chronic renal insufficiency subjected to CAPD and treated by intraperitoneal route (i.p.) with 2 ml vials of VESSEL DUE F.RTM. containing 50 mg of sulodexide. A significant increase of the peritoneal transports of urea and of creatinine joined to a significant decrease of the protein-loss in the peritoneal effluent has been observed. Significant changes of the ultrafiltration capacity and of haemorrhagic-coagulative complications have not been observed during the study.